Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733186 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects
A Phase 1 study, sponsored by Medipost.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01733186 is a Phase 1 study that has completed, run by Medipost. The registered enrollment target is 12 participants.
The verdict
NCT01733186, a Phase 1 study, has completed, sponsored by Medipost.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Interventions
- BIOLOGICAL CARTISTEM®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-01-07 |
| Est. Completion | 2017-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733186
The ClinicalTrials.gov registry entry for NCT01733186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medipost, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CARTISTEM® is the first listed.
NCT01733186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733186 about?
NCT01733186 is a clinical study titled "Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects". The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
What is the current status of trial NCT01733186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-01-07. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT01733186?
The interventions under investigation include: CARTISTEM® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01733186?
This trial is sponsored by Medipost, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.